Eric Ostertag Insider Information
Dr. Ostertag directed Poseida’s spin out from Transposagen in February 2015 and has served as our Chief Executive Officer and as a member of our board of directors since May 2015. From October 2003 to July 2015, Dr. Ostertag founded and served as the Chief Executive Officer and President of Transposagen Biopharmaceuticals, Inc., a biotechnology company that commercializes early gene editing technology in the research reagent space. Dr. Ostertag previously co-founded and served as Chief Executive Officer and President of Vindico NanoBioTechnology, Inc., a biotechnology company engaged in the discovery, development, and commercialization of human therapeutics that are based on a nanometer-scale particulate technology. Dr. Ostertag also co-founded and served as Executive Vice President of PhenoTech, Inc., a biotechnology company engaged in the discovery, development, and commercialization of reagents for diagnostic use in blood banks. Dr. Ostertag received both his Ph.D. in molecular biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in genetics from the University of Wisconsin-Madison.
What is Eric Ostertag's net worth?
The estimated net worth of Eric Ostertag is at least $3.13 million as of August 8th, 2022. Dr. Ostertag owns 838,824 shares of Poseida Therapeutics stock worth more than $3,128,814 as of August 11th. This net worth approximation does not reflect any other assets that Dr. Ostertag may own. Additionally, Dr. Ostertag receives an annual salary of $667,420.00 as CEO at Poseida Therapeutics. Learn More about Eric Ostertag's net worth.
How old is Eric Ostertag?
What is Eric Ostertag's salary?
As the CEO of Poseida Therapeutics, Inc., Dr. Ostertag earned a total compensation package of $6,294,765.00 in 2021. Dr. Ostertag earned a salary of $440,246.00, options awards of $5,627,347.00, non-equity compensation of $217,920.00, and other compensation of $9,252.00. Learn More on Eric Ostertag's salary.
How do I contact Eric Ostertag?
The corporate mailing address for Dr. Ostertag and other Poseida Therapeutics executives is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Poseida Therapeutics can also be reached via phone at 858-779-3100. Learn More on Eric Ostertag's contact information.
Has Eric Ostertag been buying or selling shares of Poseida Therapeutics?
During the last ninety days, Eric Ostertag has bought $499,999.50 in shares of Poseida Therapeutics stock and sold $592,968.24 in shares of Poseida Therapeutics stock. Most recently, on Monday, August 8th, Eric Ostertag bought 142,857 shares of Poseida Therapeutics stock. The stock was acquired at an average cost of $3.50 per share, with a total value of $499,999.50. Following the completion of the transaction, the chairman now directly owns 838,824 shares of the company's stock, valued at $2,935,884. Learn More on Eric Ostertag's trading history.
Who are Poseida Therapeutics' active insiders?
Are insiders buying or selling shares of Poseida Therapeutics?
During the last twelve months, Poseida Therapeutics insiders bought shares 11 times. They purchased a total of 2,469,975 shares worth more than $9,260,612.00. During the last twelve months, insiders at the sold shares 6 times. They sold a total of 243,649 shares worth more than $1,225,702.98. The most recent insider tranaction occured on August, 8th when Chairman Eric Ostertag bought 142,857 shares worth more than $499,999.50. Insiders at Poseida Therapeutics own 29.2 % of the company. Learn More about insider trades at Poseida Therapeutics.
Information on this page was last updated on 8/8/2022.
Eric Ostertag Insider Trading History at Poseida Therapeutics
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Poseida Therapeutics Company Overview
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
50 Day Range
2 Week Range